NeuroPace’s (NPCE) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of NeuroPace (NASDAQ:NPCE) in a report issued on Wednesday,Benzinga reports. Cantor Fitzgerald currently has a $17.00 price objective on the stock. Cantor Fitzgerald also issued estimates for NeuroPace’s FY2025 earnings at ($0.87) EPS.

Other equities analysts have also issued research reports about the stock. Wells Fargo & Company raised their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research report on Thursday, January 30th. UBS Group began coverage on shares of NeuroPace in a research report on Tuesday, January 21st. They set a “buy” rating and a $17.00 price objective on the stock. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $15.00.

NeuroPace Stock Performance

NPCE stock opened at $17.49 on Wednesday. The company has a debt-to-equity ratio of 6.03, a quick ratio of 4.77 and a current ratio of 5.59. The stock has a market cap of $572.85 million, a P/E ratio of -17.49 and a beta of 2.04. The firm has a 50 day simple moving average of $11.97 and a 200 day simple moving average of $11.56. NeuroPace has a 52 week low of $5.45 and a 52 week high of $17.85.

NeuroPace (NASDAQ:NPCE) last issued its quarterly earnings data on Tuesday, May 13th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.05. The firm had revenue of $22.52 million for the quarter, compared to analyst estimates of $21.85 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. Research analysts anticipate that NeuroPace will post -1 earnings per share for the current fiscal year.

Insider Transactions at NeuroPace

In related news, insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $13.72, for a total transaction of $1,074,742.48. Following the transaction, the insider now owns 81,993 shares in the company, valued at $1,124,943.96. This represents a 48.86% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 5,517,315 shares of company stock worth $53,285,641. Insiders own 22.20% of the company’s stock.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in NPCE. BNP Paribas Financial Markets bought a new stake in shares of NeuroPace in the 4th quarter valued at about $29,000. GAMMA Investing LLC bought a new stake in shares of NeuroPace in the 1st quarter valued at about $53,000. Wells Fargo & Company MN increased its stake in shares of NeuroPace by 54.2% in the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after acquiring an additional 2,279 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of NeuroPace by 106.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock valued at $84,000 after acquiring an additional 6,181 shares during the last quarter. Finally, MetLife Investment Management LLC bought a new stake in shares of NeuroPace in the 4th quarter valued at about $103,000. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.